American Funds®

GROWTH FUNDS

®

267 Total Holdings:
As of 3/31/15 (updated quarterly, upon availability).
All Holdings: 1 - 15 of 267
Asset Type
Amgen Inc. Equity 8,398,080 $1,342,433,088.00 2.9%
Gilead Sciences, Inc. Equity 12,412,706 $1,218,058,840.00 2.63%
Alexion Pharmaceuticals, Inc. Equity 5,426,327 $940,382,469.00 2.03%
UnitedHealth Group Inc. Equity 7,895,706 $933,983,063.00 2.01%
Oracle Corp. Equity 20,786,000 $896,915,900.00 1.93%
Netflix, Inc. Equity 1,975,000 $822,962,750.00 1.78%
Precision Castparts Corp. Equity 3,907,804 $820,638,840.00 1.77%
Accenture PLC, Class A Equity 8,734,600 $818,344,674.00 1.77%
BioMarin Pharmaceutical Inc. Equity 6,497,459 $809,713,341.00 1.75%
Stryker Corp. Equity 7,033,552 $648,845,172.00 1.4%
Avago Technologies Ltd. Equity 4,903,195 $622,607,701.00 1.34%
Amazon.com, Inc. Equity 1,664,000 $619,174,400.00 1.34%
Texas Instruments Inc. Equity 10,667,000 $609,992,395.00 1.32%
Cognizant Technology Solutions Corp., Class A Equity 9,293,000 $579,790,270.00 1.25%
Progressive Corp. Equity 19,929,555 $542,083,896.00 1.17%
All Holdings: 1 - 15 of 267

Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.

Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.

  1. Excludes certain securities in initial period of acquisition.

For more information about the risks associated with each fund, go to its detailed fund information page or read the prospectus.